MARKET

ARVN

ARVN

Arvinas
NASDAQ
13.48
+0.52
+4.01%
After Hours: 13.48 0 0.00% 19:56 02/06 EST
OPEN
13.14
PREV CLOSE
12.96
HIGH
13.62
LOW
13.12
VOLUME
605.32K
TURNOVER
--
52 WEEK HIGH
20.38
52 WEEK LOW
5.90
MARKET CAP
865.74M
P/E (TTM)
-16.7474
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARVN last week (0126-0130)?
Weekly Report · 6d ago
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth
Simply Wall St · 01/27 10:18
Weekly Report: what happened at ARVN last week (0119-0123)?
Weekly Report · 01/26 09:19
Weekly Report: what happened at ARVN last week (0112-0116)?
Weekly Report · 01/19 09:21
Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
TipRanks · 01/16 17:05
Weekly Report: what happened at ARVN last week (0105-0109)?
Weekly Report · 01/12 09:20
The Analyst Verdict: Arvinas In The Eyes Of 7 Experts
Benzinga · 01/06 14:01
Arvinas Raised to Buy From Neutral by Citigroup
Dow Jones · 01/06 13:38
More
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Webull offers Arvinas Inc stock information, including NASDAQ: ARVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARVN stock methods without spending real money on the virtual paper trading platform.